The potential of placental growth factor in the diagnosis and management of pre-eclampsia

References

• ACOG Committee on Obstetric Practice. Practice bulletin 33: Diagnosis and management of preeclampsia and eclampsia. Obstet. Gynecol. 99(1), 159–167 (2002).
   PubMed Web of Science ®Google Scholar
• Cantwell R, Clutton-Brock T, Cooper G et al. Saving Mothers’ Lives: Reviewing maternal deaths to make motherhood safer: 2006–2008. The Eighth Report of the Confidential Enquiries into Maternal Deaths in the United Kingdom. BJOG. 118(Suppl. 1), 1–203 (2011).
   PubMedGoogle Scholar
• National Institute for Health and Clinical Excellence. Hypertension in pregnancy: the management of hypertensive disorders during pregnancy. RCOG Press, London, UK (2010).
   Google Scholar
• Altman D, Carroli G, Duley L et al.; Magpie Trial Collaboration Group. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial. Lancet 359(9321), 1877–1890 (2002).
   PubMed Web of Science ®Google Scholar
• Menzies J, Magee LA, Li J et al.; Preeclampsia Integrated Estimate of RiSk (PIERS) Study Group. Instituting surveillance guidelines and adverse outcomes in preeclampsia. Obstet. Gynecol. 110(1), 121–127 (2007).
   PubMed Web of Science ®Google Scholar
• Meis PJ, Goldenberg RL, Mercer BM et al. The preterm prediction study: risk factors for indicated preterm births. Maternal-Fetal Medicine Units Network of the National Institute of Child Health and Human Development. Am. J. Obstet. Gynecol. 178(3), 562–567 (1998).
   PubMed Web of Science ®Google Scholar
• Lydon-Rochelle MT, Cárdenas V, Nelson JC, Holt VL, Gardella C, Easterling TR. Induction of labor in the absence of standard medical indications: incidence and correlates. Med. Care 45(6), 505–512 (2007).
   PubMed Web of Science ®Google Scholar
• Menzies J, Magee LA, Macnab YC et al. Current CHS and NHBPEP criteria for severe preeclampsia do not uniformly predict adverse maternal or perinatal outcomes. Hypertens. Pregnancy 26(4), 447–462 (2007).
   PubMed Web of Science ®Google Scholar
• Meads C, Cnossen J, Meher S et al. Methods of prediction and prevention of pre-eclampsia: systematic reviews of accuracy and effectiveness literature with economic modelling. Health Technol. Assess. 12(6), 1–270 (2008).
   Web of Science ®Google Scholar
• Redman CW, Sargent IL. Pre-eclampsia, the placenta and the maternal systemic inflammatory response – a review. Placenta 24(Suppl. A), S21–S27 (2003).
   PubMed Web of Science ®Google Scholar
• Levine RJ, Maynard SE, Qian C et al. Circulating angiogenic factors and the risk of preeclampsia. N. Engl. J. Med. 350(7), 672–683 (2004).
   PubMed Web of Science ®Google Scholar
• Levine RJ, Lam C, Qian C et al.; CPEP Study Group. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N. Engl. J. Med. 355(10), 992–1005 (2006).
   PubMed Web of Science ®Google Scholar
• Verlohren S, Galindo A, Schlembach D et al. An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia. Am. J. Obstet. Gynecol. 202(2), 161.e1–161.e11 (2010).
   PubMed Web of Science ®Google Scholar
• Rana S, Karumanchi SA, Levine RJ et al. Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia. Hypertension 50(1), 137–142 (2007).
   PubMed Web of Science ®Google Scholar
• Romero R, Nien JK, Espinoza J et al. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J. Matern. Fetal. Neonatal. Med. 21(1), 9–23 (2008).
   PubMed Web of Science ®Google Scholar
• Knudsen U, Kronborg C, von Dadelszen P et al. A single rapid point-of-care placental growth factor determination as an aid in the diagnosis of preeclampsia. Pregnancy Hypertension 2(1), 8–15 (2012).
   PubMed Web of Science ®Google Scholar
• Tidwell SC, Ho HN, Chiu WH, Torry RJ, Torry DS. Low maternal serum levels of placenta growth factor as an antecedent of clinical preeclampsia. Am. J. Obstet. Gynecol. 184(6), 1267–1272 (2001).
   PubMed Web of Science ®Google Scholar
• Robinson CJ, Johnson DD, Chang EY, Armstrong DM, Wang W. Evaluation of placenta growth factor and soluble Fms-like tyrosine kinase 1 receptor levels in mild and severe preeclampsia. Am. J. Obstet. Gynecol. 195(1), 255–259 (2006).
   PubMed Web of Science ®Google Scholar